
    
      The study will start with a dose escalation part of single-agent ABSK021 administered in
      repeated 28-day cycles in patients with advanced solid for safety and tolerability. The
      expansion part of oral ABSK021 at recommended dose of expansion (RDE) will be followed for
      further evaluating safety and tolerability among selected tumor types. Preliminary antitumor
      activity will also be assessed.
    
  